

Jesus Yamamoto-Furusho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4907898/publications.pdf>

Version: 2024-02-01

143
papers

3,393
citations

159585

30
h-index

182427

51
g-index

154
all docs

154
docs citations

154
times ranked

5018
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in chronic idiopathic ulcerative colitis epidemiological pattern in Mexico in a tertiary care hospital. <i>Gaceta Medica De Mexico</i> , 2023, 157, 147-153.	0.3	0
2	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	4.4	9
3	Association of dietary fiber consumption with disease activity in ulcerative colitis: An exploratory study in the Mexican population. <i>Gaceta Medica De Mexico</i> , 2022, 158, 41-47.	0.3	0
4	Diagnostic Delay of Inflammatory Bowel Disease Is Significantly Higher in Public versus Private Health Care System in Mexican Patients. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 72-80.	1.9	4
5	Expression of TOB/BTG family members in patients with inflammatory bowel disease. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e13004.	2.7	11
6	Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: Cross-sectional study. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12962.	2.7	12
7	Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2021, 44, 206-213.	0.1	0
8	Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease. <i>GastroenterologÅa Y HepatologÅa</i> , 2021, 44, 206-213.	0.5	10
9	Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. <i>GastroenterologÅa Y HepatologÅa</i> , 2021, 44, 711-718.	0.5	3
10	Intestinal production of secreted protein acidic and rich in cysteine (SPARC) in patients with ulcerative colitis. <i>Immunobiology</i> , 2021, 226, 152095.	1.9	6
11	Gene expression profiling of inflammatory cytokines in esophageal biopsies of different phenotypes of gastroesophageal reflux disease: a cross-sectional study. <i>BMC Gastroenterology</i> , 2021, 21, 201.	2.0	14
12	AKAP12/Gravin is over-expressed in patients with ulcerative colitis. <i>Immunologic Research</i> , 2021, 69, 429-435.	2.9	3
13	ABCC7/CFTR Expression Is Associated with the Clinical Course of Ulcerative Colitis Patients. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-7.	1.5	2
14	Differential Cytokine Expression in the Duodenum and Rectum of Children with Non-Immunoglobulin E-Mediated Cow's Milk Protein Allergy. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3769-3775.	2.3	6
15	Depression and Anxiety Disorders Impact in the Quality of Life of Patients with Inflammatory Bowel Disease. <i>Psychiatry Journal</i> , 2021, 2021, 1-7.	1.5	2
16	Emerging therapeutic options in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 8242-8261.	3.3	12
17	Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2021, 44, 711-718.	0.1	0
18	Mortality and Hospitalizations in Mexican Patients with Inflammatory Bowel Disease: Results from a Nationwide Health Registry. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-8.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Synthesis of Interleukin-10 in Patients with Ulcerative Colitis and <i>Helicobacter pylori</i> Infection. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	1.5	4
20	Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-5.	1.5	5
21	Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 200-204.	1.9	2
22	TRPV Subfamily (TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6) Gene and Protein Expression in Patients with Ulcerative Colitis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	2.2	14
23	Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study. <i>Digestive and Liver Disease</i> , 2020, 52, 869-877.	0.9	11
24	Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-11.	3.0	23
25	Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2020, 15, e0231988.	2.5	15
26	Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells. <i>Cellular Signalling</i> , 2020, 72, 109636.	3.6	59
27	Mental Health Factors Associated With Fatigue in Mexican Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, Publish Ahead of Print, 609-614.	2.2	1
28	Validación de un nuevo Índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. <i>Revista De Gastroenterología De México</i> , 2019, 84, 317-325.	0.2	10
29	Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000–2017). <i>Medicine (United States)</i> , 2019, 98, e16291.	1.0	35
30	Evaluación del esquema de vacunación y cuidados con relación al seguimiento y tratamiento de los pacientes con enfermedad inflamatoria intestinal. <i>Revista De Gastroenterología De México</i> , 2019, 84, 11-17.	0.2	1
31	Validación de Belief Medicines Questionnaire y Self-efficacy for Appropriate Medication Use Scale para medir adherencia al tratamiento farmacológico en pacientes con enfermedad inflamatoria intestinal. <i>Gaceta Medica De Mexico</i> , 2019, 155, 124-129.	0.3	0
32	Incidence and Indicators of Suboptimal Response to Tumor Necrosis Factor Antagonist Therapy in Inflammatory Bowel Disease in Newly Industrialized Countries: Results From the EXPLORE Study. <i>American Journal of Gastroenterology</i> , 2019, 114, S470-S470.	0.4	0
33	Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. <i>Revista De Gastroenterología De México</i> , 2018, 83, 144-167.	0.2	22
34	Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México. <i>Revista De Gastroenterología De México</i> , 2018, 83, 414-423.	0.2	4
35	Joint involvement in Mexican patients with ulcerative colitis: a hospital-based retrospective study. <i>Clinical Rheumatology</i> , 2018, 37, 677-682.	2.2	6
36	Differential Expression of IL-36 Family Members and IL-38 by Immune and Nonimmune Cells in Patients with Active Inflammatory Bowel Disease. <i>BioMed Research International</i> , 2018, 2018, 1-12.	1.9	47

#	ARTICLE	IF	CITATIONS
37	Escala de Ansiedad y Depresi3n Hospitalaria (HADS): Validaci3n en pacientes mexicanos con enfermedad inflamatoria intestinal. Gastroenterolog3a Y Hepatolog3a, 2018, 41, 477-482.	0.5	27
38	Hospital Anxiety and Depression Scale (HADS): Validation in Mexican patients with inflammatory bowel disease. Gastroenterolog3a Y Hepatolog3a (English Edition), 2018, 41, 477-482.	0.1	12
39	The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis. Mediators of Inflammation, 2018, 2018, 1-7.	3.0	13
40	Inflammatory bowel disease therapy. Current Opinion in Gastroenterology, 2018, 34, 187-193.	2.3	49
41	Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. Journal of Inflammation, 2018, 15, 13.	3.4	19
42	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy3 Access to Rapid Treatment (iSTART) approach. Intestinal Research, 2018, 16, 522-528.	2.6	17
43	Consenso mexicano sobre probi3ticos en gastroenterolog3a. Revista De Gastroenterolog3a De M3xico, 2017, 82, 156-178.	0.2	20
44	Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn's and Colitis Organisation (PANCCO) (Segunda parte). Revista De Gastroenterolog3a De M3xico, 2017, 82, 134-155.	0.2	4
45	Diagn3stico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista De Gastroenterolog3a De M3xico, 2017, 82, 46-84.	0.2	22
46	Expression of Genes Associated with Inflammation in Biopsies of Esophageal Mucosa of different Phenotypes of Gastroesophageal Reflux Disease. Gastroenterology, 2017, 152, S237.	1.3	0
47	Role of IL-38 and its Antagonist in Patients with Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S762.	1.3	1
48	Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 197-204.	0.7	9
49	Effect of Cis-palmitoleic acid supplementation on inflammation and expression of HNF43, HNF44 and IL6 in patients with ulcerative colitis. Minerva Gastroenterology, 2017, 63, 257-263.	0.5	13
50	Sa1848 IL34 and IL36 Family Expressing Cytotoxic T cells and Plasmacytoid Dendritic Cells are Increased in Patients With Active Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S379-S380.	1.3	0
51	Mo1930 Transcriptome Analysis of Immune Innate Response Genes in the Colonic Mucosa from Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, S819.	1.3	0
52	Interleukin 27 is up-regulated in patients with active inflammatory bowel disease. Immunologic Research, 2016, 64, 901-907.	2.9	23
53	Tu1981 The Oxido-reductases Enzymes (TDO2 and SOD2) in Colonic Mucosa are Markers Associated with Histological Activity and Clinical Course in Ulcerative Colitis. Gastroenterology, 2016, 150, S996.	1.3	0
54	Polimorfismos gen3ticos de interleucina-22 en pacientes con colitis ulcerosa. Revista De Gastroenterolog3a De M3xico, 2016, 81, 86-90.	0.2	3

#	ARTICLE	IF	CITATIONS
55	Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. <i>Immunology Letters</i> , 2016, 172, 79-83.	2.5	24
56	Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2683-2695.	1.9	14
57	Frequency, Clinical Features and Factors Associated with Pouchitis after Proctocolectomy with ileo-Pouch-Anal Anastomosis in Patients with Ulcerative Colitis: A Latin-American Country Retrospective-Cohort Study. <i>Digestive Surgery</i> , 2015, 32, 489-495.	1.2	7
58	Immunoregulatory Pathways Involved in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2188-2193.	1.9	83
59	Mild Clinical Behaviour of Crohn Disease in Elderly Patients in a Latin American Country: A Case-Control Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 435-439.	1.9	5
60	Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	3.0	29
61	Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. <i>Cytokine</i> , 2015, 75, 389-402.	3.2	66
62	Su1257 The Gene Expression of SPARC in the Colonic Mucosa Is Associated With Histological Activity in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 148, S-453.	1.3	1
63	Mo1712 Role of Interleukin 27 (IL-27) in the Colonic Mucosa of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, S-692.	1.3	1
64	Evaluation of diet pattern related to the symptoms of mexican patients with Ulcerative Colitis (UC): through the validity of a questionnaire. <i>Nutrition Journal</i> , 2015, 14, 25.	3.4	11
65	Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis. <i>Disease Markers</i> , 2014, 2014, 1-7.	1.3	22
66	Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study. <i>Clinical and Experimental Immunology</i> , 2014, 177, 64-75.	2.6	58
67	Association of the interleukin 15 (IL-15) gene polymorphisms with the risk of developing ulcerative colitis in Mexican individuals. <i>Molecular Biology Reports</i> , 2014, 41, 2171-2176.	2.3	13
68	High Gene Expression of CXCL8 Is Associated with the Presence of Extraintestinal Manifestations and Long-term Disease in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E22-E23.	1.9	6
69	IL-10 ^{hi} and IL-20 ^{hi} Expressing Epithelial and Inflammatory Cells are Increased in Patients with Ulcerative Colitis. <i>Journal of Clinical Immunology</i> , 2013, 33, 640-648.	3.8	58
70	Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis. <i>Immunology Letters</i> , 2013, 149, 50-53.	2.5	13
71	Gene and protein expression of centaurin beta 1 (CENTB1) are up-regulated in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e238-e239.	1.3	3
72	Indoleamine 2,3-Dioxygenase: Expressing Cells in Inflammatory Bowel Disease—A Cross-Sectional Study. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	17

#	ARTICLE	IF	CITATIONS
73	Interleukins Involved in Inflammatory Bowel Disease as New Therapeutic Targets. <i>Current Immunology Reviews</i> , 2013, 9, 86-92.	1.2	4
74	Leiden V Factor and Spastic Cerebral Palsy in Mexican Children. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 978-980.	0.7	7
75	Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut</i> , 2012, 61, 706-712.	12.1	39
76	Differential expression of occludin in patients with ulcerative colitis and healthy controls. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E1999.	1.9	30
77	Gene expression of solute carrier family 9 (Sodium/Hydrogen Exchanger) 3, (SLC9A3) is downregulated in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1197-1198.	1.9	9
78	Reduced expression of mucin 9 (MUC9) in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E601.	1.9	9
79	Differential Expression of Disc Large Homologue 5 (DLG5) and Carnitine Organic Cation Transporter (OCTN) Genes in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, S-422.	1.3	0
80	Factors Associated With Use of Azathioprine in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, S-791.	1.3	0
81	Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. <i>Human Immunology</i> , 2011, 72, 1029-1032.	2.4	33
82	Interleukin 1 $\hat{1}^2$ (IL-1B) and IL-1 Antagonist Receptor (IL-1RN) Gene Polymorphisms are Associated With the Genetic Susceptibility and Steroid Dependence in Patients With Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 531-535.	2.2	48
83	Transcript levels of Toll-Like receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. <i>BMC Gastroenterology</i> , 2011, 11, 138.	2.0	58
84	Peroxisome proliferator-activated receptor-gamma (PPAR- $\hat{1}^3$) expression is downregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 680-681.	1.9	40
85	Increased expression of discs large homolog 5 gene (DLG5) in ulcerative colitis patients compared to healthy individuals. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1639.	1.9	2
86	Gene expression of carnitine organic cation transporters 1 and 2 (OCTN) is downregulated in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2205-2206.	1.9	11
87	Role of the interleukin 24 in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2209-2210.	1.9	7
88	Interleukin-18 upregulation is associated with the use of steroids in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E50-E51.	1.9	4
89	Expression of HNF4 $\hat{1}^3$ is downregulated in patients with active ulcerative colitis (UC) compared to UC patients in remission and healthy controls. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E91.	1.9	6
90	Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E135-E136.	1.9	26

#	ARTICLE	IF	CITATIONS
91	Quantification of low expressed SCD1 gene in colonic mucosa from patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E155.	1.9	7
92	Genetic Susceptibility in Inflammatory Bowel Disease. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010, 8, 149-159.	0.8	0
93	Cytomegalovirus Infection in Patients Who Required Colectomy for Toxic Megacolon or Severe Steroid-Refractory Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 867-868.	2.3	11
94	High Gene Expression of MDR1 (ABCB1) is Associated with Medical Treatment Response and Long-Term Remission in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 541-542.	1.9	11
95	Interleukin 21 Expression is Increased in Rectal Biopsies from Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1090.	1.9	16
96	MDP-NOD2 stimulation induces HNP-1 secretion, which contributes to NOD2 antibacterial function. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 736-742.	1.9	29
97	TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1267-1268.	1.9	16
98	Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1823.	1.9	25
99	HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis. <i>Colorectal Disease</i> , 2010, 12, 1231-1235.	1.4	9
100	Prevalence and factors associated with the presence of Abnormal Function Liver Tests in patients with ulcerative colitis. <i>Annals of Hepatology</i> , 2010, 9, 397-401.	1.5	28
101	Intestinal Protozoa Infections among Patients with Ulcerative Colitis: Prevalence and Impact on Clinical Disease Course. <i>Digestion</i> , 2010, 82, 18-23.	2.3	73
102	Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. <i>Annals of Hepatology</i> , 2010, 9, 397-401.	1.5	5
103	Rheumatic manifestations of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 5517.	3.3	80
104	Distinguishing Between Anti-Neutrophil Cytoplasmic Antibody Patterns in Inflammatory Bowel Disease: Is the "Atypical Pattern" Adding More Information?. <i>American Journal of Gastroenterology</i> , 2009, 104, 1854-1855.	0.4	8
105	Association of GIST and Somatostatinoma in a Patient With Type-1 Neurofibromatosis: Is There a Common Pathway?. <i>American Journal of Gastroenterology</i> , 2009, 104, 797-799.	0.4	17
106	Growth factors as treatment for inflammatory bowel disease: A concise review of the evidence toward their potential clinical utility. <i>Saudi Journal of Gastroenterology</i> , 2009, 15, 208.	1.1	10
107	Antinuclear antibodies: A marker associated with steroid dependence in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1039-1043.	1.9	20
108	Clinical Epidemiology of Ulcerative Colitis in Mexico. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 221-224.	2.2	42

#	ARTICLE	IF	CITATIONS
109	Infliximab as a Rescue Therapy for Hospitalized Patients with Severe Ulcerative Colitis Refractory to Systemic Corticosteroids. <i>Digestive Surgery</i> , 2008, 25, 383-386.	1.2	20
110	Role of cytokines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 4280.	3.3	552
111	New treatment options in the management of IBD – focus on colony stimulating factors. <i>Biologics: Targets and Therapy</i> , 2008, 2, 501.	3.2	10
112	Factors that influence outcome in non-invasive and invasive treatment in polycystic liver disease patients. <i>World Journal of Gastroenterology</i> , 2008, 14, 3195.	3.3	8
113	Rheumatoid Arthritis Associated With Pemphigus Foliaceus in a Patient Not Taking Penicillamine. <i>Skinmed</i> , 2007, 6, 252-254.	0.0	2
114	Genetic factors associated with the development of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 5594.	3.3	31
115	Basic and clinical aspects of osteoporosis in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 6156.	3.3	48
116	HLA-DRB1*08 allele may help to distinguish between type 1 diabetes mellitus and type 2 diabetes mellitus in Mexican children. <i>Pediatric Diabetes</i> , 2007, 8, 5-10.	2.9	7
117	Association of HLA-DRB1*16 with chronic discoid lupus erythematosus in Mexican mestizo patients. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 435-438.	1.3	31
118	HLA-DRB1*0101 is associated with the genetic susceptibility to develop lichen planus in the Mexican Mestizo population. <i>Archives of Dermatological Research</i> , 2007, 299, 405-407.	1.9	15
119	Basic and clinical aspects of osteoporosis in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 6156.	3.3	46
120	Innovative therapeutics for inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 1893.	3.3	30
121	Novel genetic markers in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 5560.	3.3	55
122	Innate immunity in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 5577.	3.3	63
123	Association of HLA-DR3 and HLA-DR4 with Sinonasal Polyposis in Mexican Mestizos. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 135, 90-93.	1.9	17
124	Centaurin Î²1 Down-regulates Nucleotide-binding Oligomerization Domains 1- and 2-dependent NF-Î²B Activation. <i>Journal of Biological Chemistry</i> , 2006, 281, 36060-36070.	3.4	69
125	Association of the HLA-DRB1*0701 allele with perinuclear anti-neutrophil cytoplasmic antibodies in Mexican patients with severe ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2006, 12, 1617.	3.3	7
126	Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: Experience in a Mexican institution. <i>World Journal of Gastroenterology</i> , 2006, 12, 3406.	3.3	7

#	ARTICLE	IF	CITATIONS
127	Crohn's disease: Innate immunodeficiency?. <i>World Journal of Gastroenterology</i> , 2006, 12, 6751.	3.3	31
128	Role of the HLA-DQ locus in the development of chronic gastritis and gastric carcinoma in Mexican patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 7762.	3.3	9
129	HLA-DRB1*04 is associated with the genetic susceptibility to develop vitiligo in Mexican patients with autoimmune thyroid disease. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 182-183.	1.2	13
130	Association of HLA-DR4 (DRB1*0404) With Human Papillomavirus Infection in Patients With Focal Epithelial Hyperplasia. <i>Archives of Dermatology</i> , 2004, 140, 1227-31.	1.4	54
131	Polymorphisms in the promoter region of tumor necrosis factor alpha (TNF- α) and the HLA-DRB1 locus in Mexican Mestizo patients with ulcerative colitis. <i>Immunology Letters</i> , 2004, 95, 31-35.	2.5	34
132	HLA-DRB1 alleles encoding the shared epitope are associated with susceptibility to developing rheumatoid arthritis whereas HLA-DRB1 alleles encoding an aspartic acid at position 70 of the I ² -chain are protective in Mexican mestizos. <i>Human Immunology</i> , 2004, 65, 262-269.	2.4	50
133	HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2003, 10, 707-710.	3.3	17
134	Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. <i>Human Immunology</i> , 2003, 64, 119-123.	2.4	48
135	HLA Study on Two Mexican Mestizo Families with Autoimmune Thyroid Disease. <i>Autoimmunity</i> , 2002, 35, 265-269.	2.6	10
136	Tumor necrosis factor- α promoter polymorphisms in Mexican patients with systemic lupus erythematosus (SLE). <i>Genes and Immunity</i> , 2001, 2, 363-366.	4.1	74
137	Haplotype Distribution of Class II MHC Genes in Mexican Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 373-376.	1.1	36
138	Complotype SC30 Is Associated With Susceptibility to Develop Ulcerative Colitis in Mexicans. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 178-179.	2.2	15
139	HLA-DR7 in Association with Chlorpromazine-induced Lupus Anticoagulant (LA). <i>Journal of Autoimmunity</i> , 1997, 10, 579-583.	6.5	19
140	Further evidence of the role of HLA-DR4 in the genetic susceptibility to actinic prurigo. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 935-937.	1.2	63
141	Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the State of Guerrero, Mexico. <i>Mycopathologia</i> , 1997, 138, 137-141.	3.1	27
142	HLA-DR6 (possibly DRB1*1301) is associated with susceptibility to Takayasu arteritis in Mexicans. <i>Heart and Vessels</i> , 1996, 11, 277-280.	1.2	27
143	Independent Associations of the HLA-B27 Antigen and the Complement Haplotype SC21 in Chronic Anterior Uveitis. <i>Ocular Immunology and Inflammation</i> , 1996, 4, 203-206.	1.8	0